

TAKAFULINK DANA EKUITI GLOBAL

All information as at 30 April 2024 unless otherwise stated


Semua maklumat adalah seperti pada 30 April 2024 melainkan jika dinyatakan

Objective / Objektif Dana

Takafulink Dana Ekuiti Global aims to provide capital appreciation by investing in Shariah-compliant investments with exposure to the global equity markets.

Takafulink Dana Ekuiti Global bertujuan untuk menyediakan peningkatan nilai modal dengan melabur dalam sekuriti patuh Syariah melalui pendedahan terhadap pasaran ekuiti global.

Where the Fund invests Komposisi Pelaburan Dana



Asset Allocation Peruntukan Aset


	% NAV
1 abrdn Islamic World Equity Fund	99.84
2 Cash, Deposits & Others	0.16

Fund Details / Maklumat Terperinci Dana

Investment Manager / Pengurus Pelaburan	Prudential BSN Takaful Berhad
Inception Date / Tarikh Diterbitkan	08/07/2019
Current Fund Size / Saiz Dana Terkini	RM32,461,012.24
Annual Fund Management Charge / Caj Pengurusan Dana Tahunan	1.5% p.a.
Current NAV / NAB Terkini	RM1.59358

How the Fund has performed / Prestasi Dana

Performance Graph / Jaduan Prestasi Dana
Takafulink Dana Ekuiti Global Vs. MSCI ACWI Islamic (Shariah) Index



Total Price Movement Over the Following Periods / Jumlah Pergerakan Harga Dalam Tempoh Tersebut

	1 month	3 months	6 months	1 year	3 years	5 years	Since Inception
Price Movement / Pergerakan Harga	-2.59%	2.79%	17.30%	16.56%	21.90%	NA	59.36%
Benchmark / Penanda Aras	-2.66%	3.56%	15.73%	21.99%	39.13%	NA	79.41%
Outperformance / Perbezaan Prestasi	0.07%	-0.77%	1.57%	-5.43%	-17.23%	NA	-20.05%

TAKAFULINK DANA EKUITI GLOBAL

All information as at 30 April 2024 unless otherwise stated

Semua maklumat adalah seperti pada 30 April 2024 melainkan jika dinyatakan

Monthly Update / Laporan Bulanan Terkini

Fund Review & Strategy

The Fund returned -2.59% for the month, outperforming the benchmark return of -2.66% by 0.07%. Year-to-date, The Fund returned 6.45%, outperforming the benchmark return of 5.81% by 0.64%. Global equity markets ended lower in April due to heightened tensions in the Middle East and concerns that US interest rates would stay higher for longer. Iran's attack on Israel stoked fears of a wider regional conflict, although tensions eased later in the month. Stronger-than-expected economic data, particularly in the US, raised hopes for a 'soft landing'. However, with inflationary pressures still present, most of the world's major central banks have maintained a cautious stance. Investors are still factoring in interest-rate cuts in the US, Europe, and UK sometime in 2024, but these are now expected to occur later in the year than previously forecast. Boston Scientific was among the top performers after its first quarter results beat expectations and management raised forward guidance. AstraZeneca reported results in late April with the top and bottom line materially beating expectations driven by solid sales growth. TotalEnergies added value after reporting solid results. It is evaluating a US primary listing. On the negative side, Manhattan Associates lagged despite solid results. The Target Fund Manager suspect this was driven by profit taking. Asahi Intecc's share price weakness continued. This was possibly driven by some profit taking as the company trades at high valuations versus its peers. In addition, there were concerns around competition driven by J&J's acquisition of Shockwave Medical, which could negatively impact Asahi's plasma wire business. Elsewhere, Accenture suffered after its first quarter revenue came in below expectations and guidance was lowered. The Target Fund Manager started a new position in TSMC, the Taiwanese semiconductor manufacturer. The company has deep and growing moats derived from its technological advantage. As the world transitions to ever more advanced semiconductor nodes, TSMC stands to benefit.

Tinjauan & Strategi Dana

Dana menjana pulangan -2.59% pada bulan ini, mengatasi pulangan penanda aras -2.66% dengan perbezaan 0.07%. Sejak awal tahun sehingga bulan tinjauan, Dana memperoleh pulangan 6.45%, mengatasi pulangan penanda aras 5.81% dengan perbezaan 0.64%. Pasaran ekuiti global mengakhiri bulan dagangan lebih rendah pada April berikutan ketegangan yang meruncing di Timur Tengah dan kebimbangan bahawa kadar faedah US akan kekal lebih tinggi untuk lebih lama. Serangan Iran ke atas Israel semakin melebarkan kebimbangan konflik serantau, walaupun ketegangan mengendur pada akhir bulan itu. Data ekonomi yang lebih kukuh daripada jangkaan, terutamanya di US, memarakkan harapan untuk 'pendaratan lembut'. Namun begitu, dengan tekanan inflasi masih wujud, kebanyakan bank pusat utama dunia mengekalkan pendirian berhati-hati. Pelabur masih mengambil kira pemotongan kadar faedah di US, Eropah, dan UK pada tahun 2024, namun kini ia dijangka berlaku lebih lewat pada tahun ini berbanding ramalan sebelumnya. Boston Scientific antara yang berprestasi tinggi selepas keputusan suku pertamanya mengatasi jangkaan dan pihak pengurusan menaikkan panduan ke hadapan. AstraZeneca melaporkan keputusan pada akhir April dengan bahagian atas dan bawah mengatasi jangkaan secara material, didorong oleh pertumbuhan jualan yang kukuh. TotalEnergies menambah nilai selepas melaporkan hasil yang kukuh. Ia sedang menilai penyenaian utama US. Meninjau sudut negatif, Manhattan Associates ketinggalan walaupun memberikan keputusan yang kukuh. Pengurus Dana Sasaran mengesyaki ianya didorong oleh pengambilan untung. Kelemahan harga saham Asahi Intecc berterusan. Ia mungkin disebabkan oleh penebusan sebahagian keuntungan kerana syarikat ini berdagang pada penilaian tinggi berbanding rakan seangkatannya. Di samping itu, kebimbangan berlegar mengenai persaingan yang dicituskan oleh pengambilalihan J&J ke atas Shockwave Medical, lalu boleh memberi kesan negatif kepada perniagaan wayar plasma Asahi. Di tempat lain, Accenture menderita selepas pendapatan suku pertamanya berada di bawah jangkaan sementara panduan pula diturunkan. Pengurus Dana Sasaran memulakan kedudukan baharu dalam TSMC, pengeluar semikonduktor Taiwan. Syarikat itu mempunyai potensi yang cemerlang berikutan kelebihan teknologinya. Apabila dunia beralih kepada nod semikonduktor yang lebih maju, TSMC meraih manfaat.

Source / Sumber: Fund Commentary, April 2024, N/A

Disclaimer

Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units may fall as well as rise. Past performances of the funds and that of the fund managers are not necessarily indicative of future performance. The price movements indicated are not reflective of the actual return on your investments (which are subject to your premium allocation rate and deduction charges). The actual return on your invested premiums may fluctuate based on the underlying performance of the investment-linked funds. All Takafulink Dana are invested in Shariah-approved securities and/or Islamic private debt securities. This leaflet is for illustrative purposes only. For further details on the terms and conditions, please refer to the policy document. For further details on how you can invest in these funds, please refer to the respective product brochures. In the event of discrepancy between the information in this fact sheet and the policy document, the information in the policy document shall prevail.

Pelaburan adalah tertakluk kepada risiko-risiko pelaburan termasuk kemungkinan kehilangan jumlah wang pokok yang dilabur. Nilai unit mungkin naik ataupun jatuh. Prestasi masa dulu dana-dana atau pengurus-pengurus dana tidak semestinya mencerminkan prestasi masa depan. Pergerakan harga yang ditunjukkan tidak menggambarkan pulangan sebenar pelaburan anda (yang tertakluk kepada kadar peruntukan premium dan caj potongan). Pulangan sebenar ke atas premium yang anda labur mungkin berbeza, bergantung kepada prestasi dana-dana). Semua Takafulink Dana dilaburkan dalam sekuriti yang diluluskan oleh Syariah dan/atau sekuriti hutang swasta Islam. Risalah ini disediakan hanya untuk gambaran semata-mata. Sila rujuk kepada dokumen polisi untuk keterangan lanjut mengenai terma-terma dan syarat-syarat. Untuk keterangan lanjut mengenai bagaimana anda boleh melabur dalam dana-dana ini, sila rujuk kepada risalah-risalah produk yang berkenaan. Jika terdapat perbezaan di antara helaian fakta dan dokumen polisi, maklumat dalam dokumen polisi dianggap muktamad.

PRUDENTIAL BSN

TAKAFUL